MX2022004878A - Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. - Google Patents

Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.

Info

Publication number
MX2022004878A
MX2022004878A MX2022004878A MX2022004878A MX2022004878A MX 2022004878 A MX2022004878 A MX 2022004878A MX 2022004878 A MX2022004878 A MX 2022004878A MX 2022004878 A MX2022004878 A MX 2022004878A MX 2022004878 A MX2022004878 A MX 2022004878A
Authority
MX
Mexico
Prior art keywords
quinazolin
heteroaryl
pharmaceutical compositions
sup
amine derivatives
Prior art date
Application number
MX2022004878A
Other languages
English (en)
Inventor
Peter H Fuller
Mitchell H Keylor
Michael J Ardolino
Ryan W Chau
Anmol Gulati
Rebecca Elizabeth Johnson
Solomon D Kattar
Kaila A Margrey
Gregori J Morriello
Santhosh F Neelamkavil
Xin Yan
Elsie C Yu
Saez Cayetana Carmela Zarate
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022004878A publication Critical patent/MX2022004878A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a determinados derivados sustituidos de N-(heteroaril)quinazolin-2-amina de la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, en donde J, R3 y R4 , son como se define en la presente, que son inhibidores potentes de la cinasa LRRK2 y pueden ser útiles en el tratamiento o prevención de enfermedades en las que esté involucrada la cinasa LRRK2, tal como la enfermedad de Parkinson y otras enfermedades y trastornos descritos en la presente. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos y composiciones en la prevención o tratamiento contra enfermedades, tales como enfermedad de Parkinson, en donde esté involucrada la cinasa LRRK-2.
MX2022004878A 2019-10-25 2020-10-20 Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. MX2022004878A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926033P 2019-10-25 2019-10-25
PCT/US2020/056401 WO2021080929A1 (en) 2019-10-25 2020-10-20 N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Publications (1)

Publication Number Publication Date
MX2022004878A true MX2022004878A (es) 2022-05-13

Family

ID=75620799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004878A MX2022004878A (es) 2019-10-25 2020-10-20 Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.

Country Status (10)

Country Link
US (1) US20230023066A1 (es)
EP (1) EP4048261A4 (es)
JP (1) JP2023502857A (es)
KR (1) KR20220088744A (es)
CN (1) CN115243687A (es)
AU (1) AU2020371556A1 (es)
BR (1) BR112022007680A2 (es)
CA (1) CA3154247A1 (es)
MX (1) MX2022004878A (es)
WO (1) WO2021080929A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055679A1 (en) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
TW200902008A (en) * 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
MX340756B (es) * 2011-08-04 2016-07-25 Array Biopharma Inc Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
WO2014134774A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
UA119971C2 (uk) * 2013-10-10 2019-09-10 Араксіс Фарма Ллк Інгібітори g12c kras
WO2019074810A1 (en) * 2017-10-11 2019-04-18 Merck Sharp & Dohme Corp. INDAZOLYL-SPIRO [2,3] HEXANE-CARBONITRILE DERIVATIVES AS INHIBITORS OF LRRK2, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

Also Published As

Publication number Publication date
CN115243687A (zh) 2022-10-25
US20230023066A1 (en) 2023-01-26
WO2021080929A1 (en) 2021-04-29
EP4048261A1 (en) 2022-08-31
AU2020371556A1 (en) 2022-05-05
EP4048261A4 (en) 2023-11-22
BR112022007680A2 (pt) 2022-08-09
KR20220088744A (ko) 2022-06-28
CA3154247A1 (en) 2021-04-29
JP2023502857A (ja) 2023-01-26

Similar Documents

Publication Publication Date Title
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
CR20230310A (es) Inhibidores de prmt5
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX2022010011A (es) Inhibidores de prmt5 novedosos.
WO2018155916A3 (ko) 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
CR20220299A (es) Derivados de becimidazol
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof